{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:31:28Z","timestamp":1767375088480},"reference-count":41,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.dld.2013.07.008","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T19:07:42Z","timestamp":1380568062000},"page":"S343-S348","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"S5","title":["The importance of drug\u2013drug interactions in the DAA era"],"prefix":"10.1016","volume":"45","author":[{"given":"David","family":"Back","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Else","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2013.07.008_bib0005","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jhep.2012.10.027","article-title":"Clinical management of drug\u2013drug interactions in HCV therapy: challenges and solutions","volume":"58","author":"Burger","year":"2013","journal-title":"Journal of Hepatology"},{"key":"10.1016\/j.dld.2013.07.008_bib0010","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1002\/hep.25653","article-title":"Review and management of drug interactions with boceprevir and telaprevir","volume":"55","author":"Kiser","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.07.008_bib0015","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-pharmtox-011112-140254","article-title":"Direct-acting antiviral agents for hepatitis C virus infection","volume":"53","author":"Kiser","year":"2013","journal-title":"Annual Review of Pharmacology and Toxicology"},{"key":"10.1016\/j.dld.2013.07.008_bib0020","doi-asserted-by":"crossref","DOI":"10.3851\/IMP2527","article-title":"Review of drug interactions with telaprevir and antiretrovirals","author":"van Heeswijk","year":"2013","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.dld.2013.07.008_bib0025","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3851\/IMP2356","article-title":"Telaprevir: pharmacokinetics and drug interactions","volume":"17","author":"Garg","year":"2012","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.dld.2013.07.008_bib0030","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/QCO.0b013e32835c2027","article-title":"Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient","volume":"26","author":"Rodriguez-Torres","year":"2013","journal-title":"Current Opinion in Infectious Diseases"},{"key":"10.1016\/j.dld.2013.07.008_bib0035","unstructured":"http:\/\/www.hep-druginteractions.org."},{"key":"10.1016\/j.dld.2013.07.008_bib0040","unstructured":"Summary of Product Characteristics, Victrelis 200mg hard capsules. http:\/\/www.medicines.org.uk\/EMC\/medicine\/24768\/SPC\/Victrelis+200+mg+hard+capsules\/2013."},{"key":"10.1016\/j.dld.2013.07.008_bib0045","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.110.036996","article-title":"Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor","volume":"39","author":"Ghosal","year":"2011","journal-title":"Drug Metabolism and Disposition: The Biological Fate of Chemicals"},{"key":"10.1016\/j.dld.2013.07.008_bib0050","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","article-title":"Telaprevir is effective given every 8 or 12hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C","volume":"140","author":"Marcellin","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2013.07.008_bib0055","first-page":"191A","article-title":"OPTIMIZE trial: non-inferiority of twice-daily telaprevir versus administration every 8hours in treatment-naive, genotype 1 HCV infected patients","volume":"56","author":"Buti","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.07.008_bib0060","first-page":"21","article-title":"The effect of different types of food on the bioavailability of the investigational HCV protease inhibitor telaprevir","volume":"6","author":"van Heeswijk","year":"2011","journal-title":"Reviews in Antiviral Therapy & Infectious Diseases"},{"key":"10.1016\/j.dld.2013.07.008_bib0065","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1177\/0091270011419850","article-title":"Effect of telaprevir on the pharmacokinetics of midazolam and digoxin","volume":"52","author":"Garg","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.dld.2013.07.008_bib0070","unstructured":"Summary of Product Characteristics, INCIVO 375mg film coated tablets. http:\/\/www.medicines.org.uk\/EMC\/medicine\/25038\/SPC\/INCIVO+375+mg+film+coated+tablets\/2012."},{"key":"10.1016\/j.dld.2013.07.008_bib0075","unstructured":"INCIVEK Film Coated Tablets, Prescribing Information. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/201917lbl.pdf2013."},{"key":"10.1016\/j.dld.2013.07.008_bib0080","unstructured":"VICTRELIS Capsules, Prescribing Information. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/v\/victrelis\/victrelis_pi.pdf2013."},{"key":"10.1016\/j.dld.2013.07.008_bib0085","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2217\/pgs.11.44","article-title":"Transporter-mediated drug\u2013drug interactions","volume":"12","author":"Muller","year":"2011","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.dld.2013.07.008_bib0090","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/j.bcp.2012.07.032","article-title":"Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters","volume":"84","author":"Kunze","year":"2012","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.dld.2013.07.008_bib0095","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/hep.25831","article-title":"Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers","volume":"56","author":"Hulskotte","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2013.07.008_bib0100","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.cld.2012.09.013","article-title":"Management of the transplant recipient with chronic hepatitis C","volume":"17","author":"Burton","year":"2013","journal-title":"Clinics in Liver Disease"},{"key":"10.1016\/j.dld.2013.07.008_bib0105","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/lt.23542","article-title":"Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data","volume":"18","author":"Werner","year":"2012","journal-title":"Liver Transplantation: Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society"},{"key":"10.1016\/j.dld.2013.07.008_bib0110","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1128\/AAC.01151-12","article-title":"Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence","volume":"56","author":"Coilly","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2013.07.008_bib0115","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1128\/AAC.00653-11","article-title":"Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.dld.2013.07.008_bib0120","series-title":"16th Annual Meeting of HEP DART","article-title":"Pharmacokinetic evaluation of the interaction between the HCV protease inhibitor and the HMG-CoA reductase inhibitors atorvastatin and pravastatin","author":"Hulskotte","year":"2011"},{"key":"10.1016\/j.dld.2013.07.008_bib0125","unstructured":"Summary of Product Characteristics, Zyban 150mg prolonged release film-coated tablets. http:\/\/www.medicines.org.uk\/EMC\/medicine\/2948\/SPC\/Zyban+150+mg+prolonged+release+film-coated+tablets\/2012."},{"key":"10.1016\/j.dld.2013.07.008_bib0130","series-title":"16th Annual Meeting of HEP DART","article-title":"Co-administration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers","author":"Hulskotte","year":"2011"},{"key":"10.1016\/j.dld.2013.07.008_bib0135","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/cid\/cis968","article-title":"Pharmacokinetic interactions between the hepatitis c virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir","volume":"56","author":"Hulskotte","year":"2013","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.dld.2013.07.008_bib0140","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/liv.12082","article-title":"HCV therapy in HIV-infected patients","volume":"33","author":"Sulkowski","year":"2013","journal-title":"Liver International"},{"key":"10.1016\/j.dld.2013.07.008_bib0145","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s11904-012-0122-z","article-title":"HIV co-infection: new drugs in practice and in the pipeline","volume":"9","author":"Jennings","year":"2012","journal-title":"Current HIV\/AIDS Reports"},{"issue":"Suppl. 1","key":"10.1016\/j.dld.2013.07.008_bib0150","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/infdis\/jis764","article-title":"Current management of hepatitis C virus infection in patients with HIV co-infection","volume":"207","author":"Sulkowski","year":"2013","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.dld.2013.07.008_bib0155","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1097\/QAD.0b013e328357065c","article-title":"HIV protease inhibitors in combination with boceprevir: are drug\u2013drug interactions the same for all patients","volume":"26","author":"Schwarze-Zander","year":"2012","journal-title":"AIDS"},{"key":"10.1016\/j.dld.2013.07.008_bib0160","series-title":"Cytochrome P450 (CYP) interactions with the HCV protease inhibitor BI 201335 in healthy volunteers","author":"Sabo","year":"2012"},{"key":"10.1016\/j.dld.2013.07.008_bib0165","series-title":"45th Annu Meet Eur Assoc Study Liver (EASL)","article-title":"Evaluation of metabolic interactions for TMC435 via cytochrome P450 (CYP) enzymes in healthy volunteers","author":"Sekar","year":"2010"},{"key":"10.1016\/j.dld.2013.07.008_bib0170","series-title":"Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers","author":"Bernstein","year":"2009"},{"key":"10.1016\/j.dld.2013.07.008_bib0175","series-title":"62nd Am Assoc Study Liver Dis","article-title":"Evaluation of drug interaction potential of the HCV protease inhibitor asunaprevir (ASV; BMS-650032) at 200mg twice daily (BID) in metabolic cocktail and P-glycoprotein (P-gp) probe studies in healthy volunteers","author":"Eley","year":"2011"},{"key":"10.1016\/j.dld.2013.07.008_bib0180","series-title":"112th Annu Meet Am Soc Clin Pharmacol Ther.","article-title":"Danoprevir does not change the effect of ritonavir on the pharmacokinetics of cytochrome P450 3A substrate midazolam or the CYP2C9 substrate warfarin","author":"Chang","year":"2011"},{"key":"10.1016\/j.dld.2013.07.008_bib0185","series-title":"Am Soc Clin Pharmacol Ther","article-title":"Evaluation of CYP3A mediated drug interactions for \ufb01libuvir in healthy volunteers: \ufb01libuvir as an object and precipitant","author":"Purohit","year":"2010"},{"key":"10.1016\/j.dld.2013.07.008_bib0190","series-title":"58th Annu Meet Am Assoc Study Liver Dis","article-title":"Antiviral, pharmacokinetic and safety data for GS-9190, a non-nucleoside HCV NS5B polymerase inhibitor, in a phase-1 trial in HCV genotype1 infected patients","author":"Bavisotto","year":"2007"},{"key":"10.1016\/j.dld.2013.07.008_bib0195","series-title":"44th Annu Meet Eur Assoc Study Liver (EASL)","article-title":"Preclinical potency, pharmacokinetic and ADME characterization of ABT-333, a novel non-nucleoside HCV polymerase inhibitor","author":"Maring","year":"2009"},{"key":"10.1016\/j.dld.2013.07.008_bib0200","series-title":"62nd Am Assoc Study Liver Dis","article-title":"Daclatasvir has no clinically signi\ufb01cant effect on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate in healthy female subjects","author":"Bifano","year":"2011"},{"key":"10.1016\/j.dld.2013.07.008_bib0205","series-title":"62nd Am Assoc Study Liver Dis","article-title":"Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics","author":"Denning","year":"2011"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086581300251X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S159086581300251X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T07:14:15Z","timestamp":1646637255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S159086581300251X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":41,"alternative-id":["S159086581300251X"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2013.07.008","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The importance of drug\u2013drug interactions in the DAA era","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2013.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}